Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 4/2011

01-08-2011 | Review

MicroRNAs in systemic rheumatic diseases

Authors: Angela Ceribelli, Bing Yao, Paul R Dominguez-Gutierrez, Md A Nahid, Minoru Satoh, Edward KL Chan

Published in: Arthritis Research & Therapy | Issue 4/2011

Login to get access

Abstract

MicroRNAs (miRNAs) are endogenous, non-coding, single-stranded RNAs about 21 nucleotides in length. miRNAs have been shown to regulate gene expression and thus influence a wide range of physiological and pathological processes. Moreover, they are detected in a variety of sources, including tissues, serum, and other body fluids, such as saliva. The role of miRNAs is evident in various malignant and nonmalignant diseases, and there is accumulating evidence also for an important role of miRNAs in systemic rheumatic diseases. Abnormal expression of miRNAs has been reported in autoimmune diseases, mainly in systemic lupus erythematosus and rheumatoid arthritis. miRNAs can be aberrantly expressed even in the different stages of disease progression, allowing miRNAs to be important biomarkers, to help understand the pathogenesis of the disease, and to monitor disease activity and effects of treatment. Different groups have demonstrated a link between miRNA expression and disease activity, as in the case of renal flares in lupus patients. Moreover, miRNAs are emerging as potential targets for new therapeutic strategies of autoimmune disorders. Taken together, recent data demonstrate that miRNAs can influence mechanisms involved in the pathogenesis, relapse, and specific organ involvement of autoimmune diseases. The ultimate goal is the identification of a miRNA target or targets that could be manipulated through specific therapies, aiming at activation or inhibition of specific miRNAs responsible for the development of disease.
Appendix
Available only for authorised users
Literature
1.
Lee RC, Feinbaum RL, Ambros V: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993, 75: 843-854. 10.1016/0092-8674(93)90529-Y.CrossRefPubMed
2.
Krol J, Loedige I, Filipowicz W: The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 2010, 11: 597-610.PubMed
3.
4.
Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F, Croce CM: Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2002, 99: 15524-15529. 10.1073/pnas.242606799.PubMedCentralCrossRefPubMed
5.
6.
7.
Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T: Identification of novel genes coding for small expressed RNAs. Science. 2001, 294: 853-858. 10.1126/science.1064921.CrossRefPubMed
8.
Filipowicz W, Bhattacharyya SN, Sonenberg N: Mechanisms of posttranscriptional regulation by microRNAs: are the answers in sight?. Nat Rev Genet. 2008, 9: 102-114.CrossRefPubMed
9.
Fabian MR, Sonenberg N, Filipowicz W: Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem. 2010, 79: 351-379. 10.1146/annurev-biochem-060308-103103.CrossRefPubMed
10.
Zhou H, Huang X, Cui H, Luo X, Tang Y, Chen S, Wu L, Shen N: miR-155 and its star-form partner miR-155* cooperatively regulate type I interferon production by human plasmacytoid dendritic cells. Blood. 2010, 116: 5885-5894. 10.1182/blood-2010-04-280156.CrossRefPubMed
11.
Shin C, Nam JW, Farh KK, Chiang HR, Shkumatava A, Bartel DP: Expanding the microRNA targeting code: functional sites with centered pairing. Mol Cell. 2010, 38: 789-802. 10.1016/j.molcel.2010.06.005.PubMedCentralCrossRefPubMed
12.
Yao B, Li S, Jung HM, Lian SL, Abadal GX, Han F, Fritzler MJ, Chan EK: Divergent GW182 functional domains in the regulation of translational silencing. Nucleic Acids Res. 2010, 39: 2534-2547.PubMedCentralCrossRefPubMed
13.
Jakymiw A, Ikeda K, Fritzler MJ, Reeves WH, Satoh M, Chan EK: Autoimmune targeting of key components of RNA interference. Arthritis Res Ther. 2006, 8: R87-10.1186/ar1959.PubMedCentralCrossRefPubMed
14.
Eystathioy T, Chan EK, Takeuchi K, Mahler M, Luft LM, Zochodne DW, Fritzler MJ: Clinical and serological associations of autoantibodies to GW bodies and a novel cytoplasmic autoantigen GW182. J Mol Med. 2003, 81: 811-818. 10.1007/s00109-003-0495-y.CrossRefPubMed
15.
Bhanji RA, Eystathioy T, Chan EK, Bloch DB, Fritzler MJ: Clinical and serological features of patients with autoantibodies to GW/P bodies. Clin Immunol. 2007, 125: 247-256. 10.1016/j.clim.2007.07.016.PubMedCentralCrossRefPubMed
16.
Liu J, Carmell MA, Rivas FV, Marsden CG, Thomson JM, Song JJ, Hammond SM, Joshua-Tor L, Hannon GJ: Argonaute2 is the catalytic engine of mammalian RNAi. Science. 2004, 305: 1437-1441. 10.1126/science.1102513.CrossRefPubMed
17.
Meister G, Landthaler M, Patkaniowska A, Dorsett Y, Teng G, Tuschl T: Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Mol Cell. 2004, 15: 185-197. 10.1016/j.molcel.2004.07.007.CrossRefPubMed
18.
Pillai RS, Artus CG, Filipowicz W: Tethering of human Ago proteins to mRNA mimics the miRNA-mediated repression of protein synthesis. RNA. 2004, 10: 1518-1525. 10.1261/rna.7131604.PubMedCentralCrossRefPubMed
19.
Li S, Lian SL, Moser JJ, Fritzler ML, Fritzler MJ, Satoh M, Chan EK: Identification of GW182 and its novel isoform TNGW1 as translational repressors in Ago2-mediated silencing. J Cell Sci. 2008, 121: 4134-4144. 10.1242/jcs.036905.CrossRefPubMed
20.
Jakymiw A, Pauley KM, Li S, Ikeda K, Lian S, Eystathioy T, Satoh M, Fritzler MJ, Chan EK: The role of GW/P-bodies in RNA processing and silencing. J Cell Sci. 2007, 120: 1317-1323. 10.1242/jcs.03429.CrossRefPubMed
21.
Yang Z, Jakymiw A, Wood MR, Eystathioy T, Rubin RL, Fritzler MJ, Chan EK: GW182 is critical for the stability of GW bodies expressed during the cell cycle and cell proliferation. J Cell Sci. 2004, 117: 5567-5578. 10.1242/jcs.01477.CrossRefPubMed
22.
Eulalio A, Tritschler F, Izaurralde E: The GW182 protein family in animal cells: new insights into domains required for miRNA-mediated gene silencing. RNA. 2009, 15: 1433-1442. 10.1261/rna.1703809.PubMedCentralCrossRefPubMed
23.
Tritschler F, Huntzinger E, Izaurralde E: Role of GW182 proteins and PABPC1 in the miRNA pathway: a sense of deja vu. Nat Rev Mol Cell Biol. 2010, 11: 379-384.PubMed
24.
Fabian MR, Mathonnet G, Sundermeier T, Mathys H, Zipprich JT, Svitkin YV, Rivas F, Jinek M, Wohlschlegel J, Doudna JA, Chen CY, Shyu AB, Yates JR, Hannon GJ, Filipowicz W, Duchaine TF, Sonenberg N: Mammalian miRNA RISC recruits CAF1 and PABP to affect PABP-dependent deadenylation. Mol Cell. 2009, 35: 868-880. 10.1016/j.molcel.2009.08.004.PubMedCentralCrossRefPubMed
25.
Zekri L, Huntzinger E, Heimstadt S, Izaurralde E: The silencing domain of GW182 interacts with PABPC1 to promote translational repression and degradation of microRNA targets and is required for target release. Mol Cell Biol. 2009, 29: 6220-6231. 10.1128/MCB.01081-09.PubMedCentralCrossRefPubMed
26.
Eystathioy T, Chan EK, Tenenbaum SA, Keene JD, Griffith K, Fritzler MJ: A phosphorylated cytoplasmic autoantigen, GW182, associates with a unique population of human mRNAs within novel cytoplasmic speckles. Mol Biol Cell. 2002, 13: 1338-1351. 10.1091/mbc.01-11-0544.PubMedCentralCrossRefPubMed
27.
Treadwell EL, Alspaugh MA, Sharp GC: Characterization of a new antigenantibody system (Su) in patients with systemic lupus erythematosus. Arthritis Rheum. 1984, 27: 1263-1271. 10.1002/art.1780271108.CrossRefPubMed
28.
Satoh M, Langdon JJ, Chou CH, McCauliffe DP, Treadwell EL, Ogasawara T, Hirakata M, Suwa A, Cohen PL, Eisenberg RA, et al: Characterization of the Su antigen, a macromolecular complex of 100/102 and 200-kDa proteins recognized by autoantibodies in systemic rheumatic diseases. Clin Immunol Immunopathol. 1994, 73: 132-141. 10.1006/clin.1994.1179.CrossRefPubMed
29.
Vázquez-Del Mercado M, Sánchez-Orozco LV, Pauley BA, Chan JY, Chan EK, Panduro A, Maldonado González M, Jiménez-Luévanos MA, Martin-Márquez BT, Palafox-Sánchez CA, Dávalos-Rodríguez IP, Salazar-Páramo M, González-López L, Gámez-Nava JI, Satoh M: Autoantibodies to a miRNA-binding protein Argonaute2 (Su antigen) in patients with hepatitis C virus infection. Clin Exp Rheumatol. 2010, 28: 842-848.PubMed
30.
Ceribelli A, Tincani A, Cavazzana I, Franceschini F, Cattaneo R, Pauley BA, Chan JY, Chan EK, Satoh M: Anti-argonaute2 (Ago2/Su) and -Ro antibodies identified by immunoprecipitation in primary anti-phospholipid syndrome (PAPS). Autoimmunity. 2010, 44: 90-97.CrossRefPubMed
31.
Tili E, Michaille JJ, Costinean S, Croce CM: MicroRNAs, the immune system and rheumatic disease. Nat Clin Pract Rheumatol. 2008, 4: 534-541. 10.1038/ncprheum0885.CrossRefPubMed
32.
Nagata Y, Nakasa T, Mochizuki Y, Ishikawa M, Miyaki S, Shibuya H, Yamasaki K, Adachi N, Asahara H, Ochi M: Induction of apoptosis in the synovium of mice with autoantibody-mediated arthritis by the intraarticular injection of double-stranded MicroRNA-15a. Arthritis Rheum. 2009, 60: 2677-2683. 10.1002/art.24762.CrossRefPubMed
33.
Nahid MA, Pauley KM, Satoh M, Chan EK: miR-146a is critical for endotoxininduced tolerance: implication in innate immunity. J Biol Chem. 2009, 284: 34590-34599. 10.1074/jbc.M109.056317.PubMedCentralCrossRefPubMed
34.
Nahid MA, Satoh M, Chan EK: Mechanistic role of microRNA-146a in endotoxin-induced differential cross-regulation of TLR signaling. J Immunol. 2011, 186 (3): 1723-1734.PubMedCentralCrossRefPubMed
35.
Lu LF, Boldin MP, Chaudhry A, Lin LL, Taganov KD, Hanada T, Yoshimura A, Baltimore D, Rudensky AY: Function of miR-146a in controlling Treg cellmediated regulation of Th1 responses. Cell. 2010, 142: 914-929. 10.1016/j.cell.2010.08.012.PubMedCentralCrossRefPubMed
36.
Curtale G, Citarella F, Carissimi C, Goldoni M, Carucci N, Fulci V, Franceschini D, Meloni F, Barnaba V, Macino G: An emerging player in the adaptive immune response: microRNA-146a is a modulator of IL-2 expression and activation-induced cell death in T lymphocytes. Blood. 2010, 115: 265-273. 10.1182/blood-2009-06-225987.CrossRefPubMed
37.
O'Connell RM, Kahn D, Gibson WS, Round JL, Scholz RL, Chaudhuri AA, Kahn ME, Rao DS, Baltimore D: MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity. 2010, 33: 607-619. 10.1016/j.immuni.2010.09.009.PubMedCentralCrossRefPubMed
38.
Divekar AA, Dubey S, Gangalum PR, Singh RR: Dicer insufficiency and microRNA-155 overexpression in lupus regulatory T cells: an apparent paradox in the setting of an inflammatory milieu. J Immunol. 2011, 186: 924-930. 10.4049/jimmunol.1002218.PubMedCentralCrossRefPubMed
39.
Babiarz JE, Ruby JG, Wang Y, Bartel DP, Blelloch R: Mouse ES cells express endogenous shRNAs, siRNAs, and other microprocessor-independent, Dicer-dependent small RNAs. Genes Dev. 2008, 22: 2773-2785. 10.1101/gad.1705308.PubMedCentralCrossRefPubMed
40.
Bluml S, Bonelli M, Niederreiter B, Puchner A, Mayr G, Hayer S, Koenders MI, van den Berg WB, Smolen J, Redlich K: Essential role for micro-RNA 155 in the pathogenesis of autoimmune arthritis. Arthritis Rheum. 2011, 63: 1281-1288. 10.1002/art.30281.CrossRefPubMed
41.
Meister J, Schmidt MH: miR-126 and miR-126*: new players in cancer. Scientific World Journal. 2010, 10: 2090-2100.CrossRefPubMed
42.
Volinia S, Galasso M, Costinean S, Tagliavini L, Gamberoni G, Drusco A, Marchesini J, Mascellani N, Sana ME, Abu Jarour R, Desponts C, Teitell M, Baffa R, Aqeilan R, Iorio MV, Taccioli C, Garzon R, Di Leva G, Fabbri M, Catozzi M, Previati M, Ambs S, Palumbo T, Garofalo M, Veronese A, Bottoni A, Gasparini P, Harris CC, Visone R, Pekarsky Y, et al: Reprogramming of miRNA networks in cancer and leukemia. Genome Res. 2010, 20: 589-599. 10.1101/gr.098046.109.PubMedCentralCrossRefPubMed
43.
44.
Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982, 25: 1271-1277. 10.1002/art.1780251101.CrossRefPubMed
45.
Hochberg MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997, 40: 1725-CrossRefPubMed
46.
Dai Y, Huang YS, Tang M, Lv TY, Hu CX, Tan YH, Xu ZM, Yin YB: Microarray analysis of microRNA expression in peripheral blood cells of systemic lupus erythematosus patients. Lupus. 2007, 16: 939-946. 10.1177/0961203307084158.CrossRefPubMed
47.
Dai Y, Sui W, Lan H, Yan Q, Huang H, Huang Y: Comprehensive analysis of microRNA expression patterns in renal biopsies of lupus nephritis patients. Rheumatol Int. 2009, 29: 749-754. 10.1007/s00296-008-0758-6.CrossRefPubMed
48.
Tang Y, Luo X, Cui H, Ni X, Yuan M, Guo Y, Huang X, Zhou H, de Vries N, Tak PP, Chen S, Shen N: MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum. 2009, 60: 1065-1075. 10.1002/art.24436.CrossRefPubMed
49.
Zhao X, Tang Y, Qu B, Cui H, Wang S, Wang L, Luo X, Huang X, Li J, Chen S, Shen N: MicroRNA-125a contributes to elevated inflammatory chemokine RANTES via targeting KLF13 in systemic lupus erythematosus. Arthritis Rheum. 2010, 62: 3425-3435. 10.1002/art.27632.CrossRefPubMed
50.
Pan W, Zhu S, Yuan M, Cui H, Wang L, Luo X, Li J, Zhou H, Tang Y, Shen N: MicroRNA-21 and microRNA-148a contribute to DNA hypomethylation in lupus CD4+ T cells by directly and indirectly targeting DNA methyltransferase 1. J Immunol. 2010, 184: 6773-6781. 10.4049/jimmunol.0904060.CrossRefPubMed
51.
Zhao S, Wang Y, Liang Y, Zhao M, Long H, Ding S, Yin H, Lu Q: MicroRNA-126 regulates DNA methylation in CD4+ T cells and contributes to systemic lupus erythematosus by targeting DNA methyltransferase I. Arthritis Rheum. 2011, 63: 1376-1386. 10.1002/art.30196.CrossRefPubMed
52.
Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P: New therapies for treatment of rheumatoid arthritis. Lancet. 2007, 370: 1861-1874. 10.1016/S0140-6736(07)60784-3.CrossRefPubMed
53.
Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN, Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000, 343: 1594-1602. 10.1056/NEJM200011303432202.CrossRefPubMed
54.
Nakasa T, Miyaki S, Okubo A, Hashimoto M, Nishida K, Ochi M, Asahara H: Expression of microRNA-146 in rheumatoid arthritis synovial tissue. Arthritis Rheum. 2008, 58: 1284-1292. 10.1002/art.23429.PubMedCentralCrossRefPubMed
55.
Pauley KM, Satoh M, Chan AL, Bubb MR, Reeves WH, Chan EK: Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res Ther. 2008, 10: R101-10.1186/ar2344.PubMedCentralCrossRefPubMed
56.
Stanczyk J, Pedrioli DM, Brentano F, Sanchez-Pernaute O, Kolling C, Gay RE, Detmar M, Gay S, Kyburz D: Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum. 2008, 58: 1001-1009. 10.1002/art.23386.CrossRefPubMed
57.
Murata K, Yoshitomi H, Tanida S, Ishikawa M, Nishitani K, Ito H, Nakamura T: Plasma and synovial fluid microRNAs as potential biomarkers of rheumatoid arthritis and osteoarthritis. Arthritis Res Ther. 2010, 12: R86-10.1186/ar3013.PubMedCentralCrossRefPubMed
58.
Stanczyk J, Ospelt C, Karouzakis E, Filer A, Raza K, Kolling C, Gay R, Buckley CD, Tak PP, Gay S, et al: Altered expression of miR-203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblast activation. Arthritis Rheum. 2011, 63: 373-381. 10.1002/art.30115.PubMedCentralCrossRefPubMed
59.
Fulci V, Scappucci G, Sebastiani GD, Giannitti C, Franceschini D, Meloni F, Colombo T, Citarella F, Barnaba V, Minisola G, Galeazzi M, Macino G: miR-223 is overexpressed in T-lymphocytes of patients affected by rheumatoid arthritis. Hum Immunol. 2010, 71: 206-211. 10.1016/j.humimm.2009.11.008.CrossRefPubMed
60.
Alsaleh G, Suffert G, Semaan N, Juncker T, Frenzel L, Gottenberg JE, Sibilia J, Pfeffer S, Wachsmann D: Bruton's tyrosine kinase is involved in miR-346-related regulation of IL-18 release by lipopolysaccharide-activated rheumatoid fibroblast-like synoviocytes. J Immunol. 2009, 182: 5088-5097. 10.4049/jimmunol.0801613.CrossRefPubMed
61.
Niimoto T, Nakasa T, Ishikawa M, Okuhara A, Izumi B, Deie M, Suzuki O, Adachi N, Ochi M: MicroRNA-146a expresses in interleukin-17 producing T cells in rheumatoid arthritis patients. BMC Musculoskelet Disord. 2010, 11: 209-10.1186/1471-2474-11-209.PubMedCentralCrossRefPubMed
62.
Li J, Wan Y, Guo Q, Zou L, Zhang J, Fang Y, Fu X, Liu H, Lu L, Wu Y: Altered microRNA expression profile with miR-146a upregulation in CD4+ T cells from patients with rheumatoid arthritis. Arthritis Res Ther. 2010, 12: R81-10.1186/ar3006.PubMedCentralCrossRefPubMed
63.
Nakamachi Y, Kawano S, Takenokuchi M, Nishimura K, Sakai Y, Chin T, Saura R, Kurosaka M, Kumagai S: MicroRNA-124a is a key regulator of proliferation and monocyte chemoattractant protein 1 secretion in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Arthritis Rheum. 2009, 60: 1294-1304. 10.1002/art.24475.CrossRefPubMed
64.
Venables PJ: Sjogren's syndrome. Best Pract Res Clin Rheumatol. 2004, 18: 313-329.PubMed
65.
Alevizos I, Bajracharya SD, Alexander S, Turner RJ, Illei GG: MicroRNA profiling of minor salivary glands identifies disease and inflammation biomarkers in Sjogren's syndrome patients [abstract]. Arthritis Rheum. 2009, 60: S733-S734.
66.
Michael A, Bajracharya SD, Yuen PS, Zhou H, Star RA, Illei GG, Alevizos I: Exosomes from human saliva as a source of microRNA biomarkers. Oral Dis. 2010, 16: 34-38. 10.1111/j.1601-0825.2009.01604.x.PubMedCentralCrossRefPubMed
67.
Alevizos I, Illei GG: MicroRNAs in Sjogren's syndrome as a prototypic autoimmune disease. Autoimmun Rev. 2010, 9: 618-621. 10.1016/j.autrev.2010.05.009.PubMedCentralCrossRefPubMed
68.
Alevizos I, Alexander S, Turner RJ, Illei GG: MicroRNA expression profiles as biomarkers of minor salivary gland inflammation and dysfunction in Sjogren's syndrome. Arthritis Rheum. 2011, 63: 535-544.PubMedCentralCrossRefPubMed
69.
Pauley KM, Stewart CM, Gauna AE, Dupre LC, Kuklani R, Chan AL, Pauley BA, Reeves WH, Chan EK, Cha S: Altered miR-146a expression in Sjogren's syndrome and its functional role in innate immunity. Eur J Immunol. 2011, 41: 2029-2039.PubMedCentralCrossRefPubMed
70.
Mayes MD, Lacey JV, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ, Schottenfeld D: Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003, 48: 2246-2255. 10.1002/art.11073.CrossRefPubMed
71.
Maurer B, Stanczyk J, Jüngel A, Akhmetshina A, Trenkmann M, Brock M, Kowal-Bielecka O, Gay RE, Michel BA, Distler JH, Gay S, Distler O: MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum. 2010, 62: 1733-1743.CrossRefPubMed
72.
Bohan A, Peter JB: Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975, 292: 403-407. 10.1056/NEJM197502202920807.CrossRefPubMed
73.
Eisenberg I, Eran A, Nishino I, Moggio M, Lamperti C, Amato AA, Lidov HG, Kang PB, North KN, Mitrani-Rosenbaum S, Flanigan KM, Neely LA, Whitney D, Beggs AH, Kohane IS, Kunkel LM: Distinctive patterns of microRNA expression in primary muscular disorders. Proc Natl Acad Sci USA. 2007, 104: 17016-17021. 10.1073/pnas.0708115104.PubMedCentralCrossRefPubMed
74.
Bohan A, Peter JB: Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975, 292: 344-347. 10.1056/NEJM197502132920706.CrossRefPubMed
75.
Mammen AL: Dermatomyositis and polymyositis: Clinical presentation, autoantibodies, and pathogenesis. Ann N Y Acad Sci. 2010, 1184: 134-153. 10.1111/j.1749-6632.2009.05119.x.CrossRefPubMed
Metadata
Title
MicroRNAs in systemic rheumatic diseases
Authors
Angela Ceribelli
Bing Yao
Paul R Dominguez-Gutierrez
Md A Nahid
Minoru Satoh
Edward KL Chan
Publication date
01-08-2011
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 4/2011
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar3377

Other articles of this Issue 4/2011

Arthritis Research & Therapy 4/2011 Go to the issue

Review

Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis

Research article

Atypical clinical presentation of a subset of patients with anti-RNA polymerase III - non-scleroderma cases associated with dominant RNA polymerase I reactivity and nucleolar staining

Review

Negative regulation of osteoclastogenesis and bone resorption by cytokines and transcriptional repressors

Editorial

A new weapon against an old target

Research article

CD23+/CD21hi B-cell translocation and ipsilateral lymph node collapse is associated with asymmetric arthritic flare in TNF-Tg mice

Commentary

Neutrophils and interferon-α-producing cells: who produces interferon in lupus?
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits